Cassaday & Co Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Cassaday & Co Wealth Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$105K	Hold	665	–	–	﹤0.01%	470
2026 Q1	$84.9K	Buy	+665	New	+$83K	﹤0.01%	496

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Cassaday & Co Wealth Management's XBI Position: Q2 2026 in Review

Cassaday & Co Wealth Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 665 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #470.

Cassaday & Co Wealth Management first reported a position in XBI in Q1 2026 and has held it in 2 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Cassaday & Co Wealth Management held 665 shares of State Street SPDR S&P Biotech ETF worth $105K as of Q2 2026.
Cassaday & Co Wealth Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q2 2026, its #470 holding.
Cassaday & Co Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2026 and has held it in 2 quarters since.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.